



| Salt Composition: | Paracetamol (500mg) + Dicyclomine (20mg) |
| Manufacturer: | Sanofi India Ltd |
| Storage: | Below 25 degree celcius |
In Stock
Have doubts about this medicine?
Have doubts about this medicine?
Baralgan NU Tablet is a combination medicine used in the treatment of abdominal pain. It works effectively to reduce abdominal pain and cramps by relaxing the muscles of the stomach and gut. Baralgan NU Tablet is taken with or without food in a dose and duration as advised by the doctor. It is better to take it with food to avoid stomach upset. The dose you are given will depend on your condition and how you respond to the medicine. You should keep taking this medicine for as long as your doctor recommends. If you stop treatment too early your symptoms may come back and your condition may worsen. Let your healthcare team know about all other medications you are taking as some may affect or be affected by this medicine.
Baralgan NU Tablet is a combination of two medicines: dicyclomine and paracetamol which relieves abdominal pain and cramps. Dicyclomine is an anti-cholinergic which relaxes the muscles in the stomach and gut (intestine). It stops sudden muscle contractions (spasms) thereby relieving cramps, pain, bloating, and discomfort. Paracetamol is an analgesic (pain reliever) which works by blocking the release of certain chemical messengers that cause pain.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Baralgan NU Tablet may be taken with or without food but it is better to take it at a fixed time.
Alcohol
It is unsafe to consume alcohol with Baralgan NU Tablet.
Breastfeed
Baralgan NU Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Pregnancy
Baralgan NU Tablet is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.